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(CAD).
Methods: Sixty-one patients with stable CAD, documented by coronary angiography were
included in this phase I study. Patients were randomized to either single dose sildenaﬁl or matched
placebo. Speckle tracking echocardiography was done at baseline and 60 min after sildenaﬁl/pla-
cebo intake to calculate peak systolic strain (PSS) of the most severely affected myocardial segments
and the global longitudinal PSS.
Results: The baseline mean segmental PSS in the sildenaﬁl group changed by 52%, 3 ± 1% at
baseline versus 7 ± 2% after sildenaﬁl intake, P= 0.01. However, no signiﬁcant changes were
reported in the placebo group, 7 ± 3% at baseline versus 7.25 ± 3%, P= 0.1. The baseline
mean global longitudinal PSS in the sildenaﬁl group changed by 9% (15 ± 4% at baseline versus
18 ± 3% after sildenaﬁl, P= 0.03). In placebo patients, the change was only 3% from baseline
(14.8 ± 2% at baseline compared to 15 ± 2% after placebo intake, P= 0.1). Sildenaﬁl was
well tolerated without clinical or hemodynamic deterioration after its intake.
Conclusion: Sildenaﬁl intake is safe in patients with stable CAD, it induced marginal improvements
in the peak systolic strain of different myocardial ischemic territories.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Sildenaﬁl citrate is a potent orally active phosphodiesterase
type 5 inhibitor that is effective in the treatment of male erec-
tile dysfunction of organic, psychogenic or mixed etiologies
and signiﬁcantly improves rates of successful sexual
intercourse in men with erectile dysfunction.1 However, post-
marketing surveillance data after approval of sildenaﬁl by
44 M. Salem et al.the Food and Drug Administration revealed a number of seri-
ous cardiovascular events, including myocardial infarction and
sudden death from cardiac causes, temporally associated with
the use of the drug. Although it has been suggested that these
events were not unexpected given the characteristics of the
population who were prescribed sildenaﬁl, the issue which
needs explanation is that many of these events occurred only
shortly after ingestion of the drug and before any attempt at
the sexual activity.2 However, it is not possible to determine
whether these events were directly related to the use of
sildenaﬁl, the patient’s underlying cardiovascular risk, or a
combination of these and other factors such as ‘coronary
steal’. Since phosphodiesterase is also present in vascular
smooth muscle, it is hypothesized that if sildenaﬁl had any di-
rect cardiovascular effect, it could be best detected by measur-
ing the effects of this drug in those with CAD.3 Left ventricular
longitudinal mechanics at rest are attenuated in patients with
CAD, this means that measuring speckle tracking-derived lon-
gitudinal strain may be an useful tool in predicting the extent
of CAD.4 In this study we tested the safety of single dose sil-
denaﬁl in patients with chronic stable angina.2. Patients and methods
2.1. Study design
This study included 61 consecutive patients with stable CAD
who were randomly allocated into a randomized placebo-
controlled phase-I study (2:1 randomization) to either silde-
naﬁl or a matched placebo. We aimed to study the acute ef-
fect of a single dose sildenaﬁl on myocardial ischemic
territories. The study was done at the cardiology department,
Benha University Hospital, Benha, Egypt in the period from
December 2011 to December 2012. All patients signed an in-
formed consent. Key inclusion criteria were: patients with
age range 40–70 years, who have chronic stable angina doc-
umented by coronary angiography with affection of at least
one of the main epicardial coronary arteries (including the
LAD artery). Key exclusion criteria were: previous myocar-
dial infarction, previous percutaneous coronary intervention
(PCI), previous coronary artery bypass graft (CABG) opera-
tion, left main disease or single-vessel left circumﬂex (LCX)
or single-vessel right coronary artery (RCA) disease, contra-
indication to sildenaﬁl such as stenotic valvular lesions, and
patient refusal.2.2. Study protocol
Oral nitrates were discontinued 24 h before the study5; other
medications such as antiplatelets and statins were continued
as clinically indicated.
According to randomization, patients were classiﬁed into 2
groups: group-I (41 patients): were given sildenaﬁl; 50 mg oral-
ly, once, and group-II (20 patients): were given placebo (para-
cetamol 500 mg), once. Conventional and speckle tracking
echocardiographic measurements were done at baseline, and
60 min after sildenaﬁl or placebo intake. Patients were ran-
domized using simple randomization (closed envelope method)
and they were blinded to randomization. The study analysiswas done by an independent investigator who was blinded to
study randomization.
2.3. Baseline and 60 min evaluation
All patients had review of medical history, general (heart rate
and systemic blood pressure) and local cardiac examination,
routine laboratory work-up, twelve-lead surface ECG at base-
line and after sildenaﬁl/placebo intake, analysis of coronary
angiograms to classify them as having single, double, or
three-vessel disease using CASS deﬁnitions of CAD6 and ﬁnally
echocardiographic examination at baseline and after sildenaﬁl/
placebo intake in the left lateral decubitus position using a com-
mercially available system (Vivid 7, General Electric-
Vingmed). Images were obtained with a simultaneous ECG
signal.
2.3.1. Conventional echocardiography
Two dimensional images were acquired during breath hold and
saved in cine-loop format from three consecutive beats. The
biplane Simpson’s technique was used to calculate LV
end-systolic volume (ESV), LV end-diastolic volume (EDV),
and LVEF. M-mode echo was used for the measurement of
the left ventricular dimension in systole (LVIDs), and diastole
(LVIDd), interventricular septum (IVSd and IVSs), posterior
wall thickness (PWTd and PWTs), and LVEF. Pulmonary ar-
tery systolic pressure (PASP) was estimated by the maximum
velocity over the tricuspid regurgitant jet using the modiﬁed
Bernoulli equation and then adding to this value an estimated
right atrial pressure.7
2.3.2. Speckle tracking echocardiography
Apical four- and two-chamber views as well as long-axis views
were used for quantiﬁcation of peak systolic strain by auto-
mated function imaging speckle-tracking analysis. This novel
software analyses the motion by tracking frame-to-frame
movement of natural acoustic markers on standard ultrasonic
images in two dimensions. First, the LV end-systolic frame was
deﬁned by determining the closure of the aortic valve in the
apical long-axis view. Then the time interval between R-wave
and aortic valve closure was automatically measured and used
as a reference for the four- and two-chamber views. After
deﬁning the mitral annulus and LV apex with three index
points in all three apical views, the LV endocardial border
was automatically traced at end-systole and the created region
of interest manually adjusted to the thickness of the myocar-
dium. Tracking quality was then validated in all segments from
the three apical views. Finally, when all the 3 views have been
processed i.e. apical 2-chamber, apical 4-chamber and apical
long-axis views, the results were integrated and were shown
as a single ‘bull’s eye’ display with colorization according to
the peak systolic strain for each segment (range from red i.e.
better to blue i.e. worse) and this has been displayed as a
numerical value for each segment (normal cut-level range is
from 15% to 20% with positive numeric values represent-
ing dyskinetic segments), also, the global longitudinal peak
systolic strain for the complete LV was provided by the
software using the same 17-segment model in a ‘bull’s eye’ plot
calculated as the average of longitudinal peak systolic strain of
each view.8
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Data were presented as mean ± SD for continuous data and
as number (%) for qualitative ones. Student’s t test was used
for between group analysis of continuous data, while the
Chi-Square test was used for categorical data. Level of evi-
dence <0.05 was considered statistically signiﬁcant. SPSS ver-
sion 20, was used for data analysis.
4. Results
4.1. Study population
The mean age was 56 ± 8 years (range from 40 to 70 years).
Seventy-four percent were males, 30% were hypertensives,
23% had history of diabetes mellitus (DM), 57% were smok-
ers, 15% were obese, and 8% had family history of CAD. Be-
tween group analysis showed a statistically signiﬁcant
difference between the sildenaﬁl group and placebo group in
the prevalence of hypertension (32% versus 25% in sildenaﬁl
and placebo groups respectively, P= 0.018), DM (27% versus
15% in sildenaﬁl and placebo groups respectively, P= 0.004),
smoking (66% versus 40% in sildenaﬁl and placebo groups
respectively, P= 0.001), obesity (17% versus 10% in sildenaﬁl
and placebo groups respectively, P= 0.023) and family his-
tory of CAD (10% versus 5% in sildenaﬁl and placebo groups
respectively, P= 0.047) Table 1. Thirty percent of study pop-
ulation had single vessel LAD disease, 23% had 2-vessel
(LAD+ LCX) disease, 25% had 2-vessel (LAD+ RCA) dis-
ease and 23% had 3-vessel disease. Between group analysis
showed a statistically signiﬁcant difference regarding the prev-
alence of 2-vessel (LAD+ LCX) disease (7% versus 55% in
sildenaﬁl and placebo groups respectively, P= 0.001) and
prevalence of 3-vessel disease (32% versus 5% in sildenaﬁl
and placebo groups respectively, P= 0.02). There was no sta-
tistically signiﬁcant difference between groups in prevalence of
single vessel LAD disease (32% versus 25% in sildenaﬁl and
placebo groups respectively, P= 0.6) and prevalence of
2-vessel (LAD+ RCA) disease (29% versus 15% in sildenaﬁl
and placebo groups respectively, P= 0.3).
4.2. Hemodynamic data
The mean baseline heart rate (HR) was 75 ± 11.4 bpm
(76 ± 11, 72 ± 10 bpm in sildenaﬁl and placebo groups
respectively, P= 0.04). One hour after sildenaﬁl/placebo
intake, the mean HR was 77 ± 10 bpm (80 ± 10, 72 ±Table 1 Baseline characteristics.
Variable All patients n= 61
Age (years) mean ± SD 56 ± 8
Male sex, n (%) 45 (74%)
Hypertension 18 (30%)
DM 14 (23%)
Smoking 35 (57%)
Obesity 9 (15%)
Family history of premature CAD 5 (8%)
DM= diabetes mellitus, CAD= coronary artery disease.8 bpm in sildenaﬁl and placebo groups respectively,
P= 0.03). Within group analysis did not show any signiﬁcant
change in HR in the placebo group. However, HR signiﬁcantly
increased in the sildenaﬁl group from baseline to 60 min
(76 ± 11 versus 80 ± 10 bpm, P= 0.03). The mean baseline
systolic blood pressure (SBP) was 124 ± 12 mmHg
(124 ± 13, 126 ± 8 mmHg in sildenaﬁl and placebo groups
respectively, P= 0.1). One hour after sildenaﬁl/placebo in-
take, the mean SBP was 120 ± 14 mmHg (115 ± 13, 127 ±
12.5 mmHg in sildenaﬁl and placebo groups respectively,
P= 0.02). Within group analysis did not show any signiﬁcant
change in SBP in the placebo group. However, SBP showed
signiﬁcant reduction in the sildenaﬁl group from baseline to
60 min (124 ± 13 versus 115 ± 13 mmHg, P= 0.01). The
mean baseline diastolic BP (DBP) was 78 ± 9 mmHg
(78 ± 10, 79 ± 6 mmHg in sildenaﬁl and placebo groups
respectively, P= 0.09). One hour after sildenaﬁl/placebo in-
take, the mean DBP was 76 ± 10 mmHg (71 ± 11, 79 ±
7 mmHg in sildenaﬁl and placebo groups respectively,
P= 0.03). Within group analysis did not show any signiﬁcant
change in DBP in the placebo group. However, DBP showed
signiﬁcant reduction in the sildenaﬁl group from baseline to
60 min (78 ± 10 versus 71 ± 11 mmHg, P= 0.03).4.3. Adverse events after sildenaﬁl intake
Twenty-six patients (64%) were symptom free after sildenaﬁl
intake. Five patients (12%) reported dizziness, while ﬁve pa-
tients (12%) reported ﬂushing. Two patients (5%) complained
of mild nonspeciﬁc chest discomfort. Three patients (7%)
developed a sense of palpitation. All the above mentioned
symptoms were transient and do not need any intervention.4.4. Echocardiographic data
4.4.1. Conventional echocardiography
The mean baseline LVEF was 55 ± 10% (52 ± 10%,
60 ± 12% in sildenaﬁl and placebo groups respectively,
P= 0.008). The mean baseline PASP was 31 ± 11 mmHg
(31 ± 13, 31 ± 10 mmHg in sildenaﬁl and placebo groups
respectively, P= 0.2). One hour after sildenaﬁl/placebo
intake, the mean PASP was 29 ± 10.7 mmHg (29 ± 11,
30 ± 11 mmHg in sildenaﬁl and placebo groups respectively,
P= 0.03). Within group analysis did not show any signiﬁcant
change in PASP in the placebo group. However, PASP showed
signiﬁcant reduction in the sildenaﬁl group from baseline to
60 min (31 ± 13 versus 29 ± 11 mmHg, P= 0.01).Sildenaﬁl n= 41 Placebo n= 20 P value
54.0 ± 6 57 ± 8 0.081
30 (73%) 15 (75%) 0.88
13 (32%) 5 (25%) 0.018
11 (27%) 3 (15%) 0.004
27 (66%) 8 (40%) 0.001
7 (17%) 2 (10%) 0.023
4 (10%) 1 (5%) 0.047
Figure 2 Global longitudinal PSS before and after sildenaﬁl/
placebo.
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The mean baseline segmental PSS was 5 ± 2% (3 ± 1%,
7 ± 3% in sildenaﬁl and placebo groups respectively,
P= 0.02). One hour after sildenaﬁl/placebo intake, the mean
segmental PSS was 7 ± 7% (7 ± 2%, 7 ± 3% in
sildenaﬁl and placebo groups respectively, P= 0.1). Within
group analysis showed that mean segmental PSS changed by
52% (mean delta change) from baseline in the sildenaﬁl group
(3 ± 1%, 7 ± 2% at baseline and one hour after sildenaﬁl
use respectively, P= 0.01). However, in the placebo group,
mean segmental PSS changed by only 4% from baseline
(7 ± 31%, 7.25 ± 3% at baseline and one hour after
placebo use respectively, P= 0.1), Fig. 1. The mean baseline
global longitudinal PSS was 14 ± 6% (15 ± 4%, 15 ±
2% in sildenaﬁl and placebo groups respectively, P= 0.1). One
hour after sildenaﬁl/placebo intake, the mean global PSS was
16 ± 3% (18 ± 3%, 15 ± 2% in sildenaﬁl and placebo
groups respectively, P= 0.04). Within group analysis showed
that mean global PSS changed by 9% from baseline in the sil-
denaﬁl group (15 ± 4%, 18 ± 3% at baseline and one
hour after sildenaﬁl use respectively, P= 0.03). However, in
the placebo group, the mean global PSS changed only by
3% from baseline (14.8 ± 2.1%, 15.2 ± 2.2% at base-
line and one hour after placebo use respectively, P= 0.1)
(Figs. 2 and 3).
4.5. Subgroup analysis
4.5.1. Different angiographic subgroups
It was found that both mean segmental and mean global lon-
gitudinal PSS showed improvements among all angiographic
subgroups with the exception of the group with 2-vessel disease
(LAD+ LCX) where both mean segmental and mean global
PSS showed deterioration (8 ± 3% versus 1 ± 8%,
P= 0.02 for segmental PSS, and 18 ± 6% versus
17 ± 4%, P= 0.03 for global PSS).
4.5.2. Different demographic and risk factor subgroups
It was found that both mean segmental and mean global lon-
gitudinal PSS showed improvements among all subgroups,
even among female patients. However, the group with DM,
both mean segmental and mean global PSS showed deteriora-
tion (from 8 ± 5% to +2 ± 5%, P= 0.001 for segmental
PSS and from 19 ± 3% to 18 ± 2%, P= 0.2 for global
PSS).Figure 1 Segmental PSS before and after sildenaﬁl/placebo.4.6. Predictors for changes in PSS
Logistic regression analysis has been done using changes in
PSS (segmental and global) from baseline as a dependant fac-
tor, while sildenaﬁl intake, demographic data, risk factors,
number of diseased coronaries and left ventricular ejection
fraction (LVEF) were used as independent factors. It was
found that signiﬁcant independent predictors for changes in
PSS are: sildenaﬁl intake (for segmental PSS only), DM (for
segmental PSS only), presence of 2-vessel (LAD+ LCX) dis-
ease (for both segmental and global PSS) and LVEF less than
50% (for both segmental and global PSS) Table 2.
5. Discussion
With the development of phosphodiesterase-5 inhibitors, the
ﬁrst of which was sildenaﬁl, the question of safety of these
drugs, especially in patients with latent or overt CAD, became
a concern. The most recent AHA guidelines state that PDE-5
inhibitors are useful for the treatment of erectile dysfunction in
patients with stable cardiovascular disease (class-I, level of
evidence A).9 In the present study, sildenaﬁl did not cause
hemodynamic deterioration, and induced improvements in
PSS of ischemic segments among all study subgroups with
the exception of diabetics and patients with 2-vessel disease
(LAD+ LCX).
To our knowledge, this is the ﬁrst study to be done using
such a protocol and the previous clinical experience in this sit-
uation is very limited. However, few studies had examined the
effect of sildenaﬁl (especially the acute effect) in patients with
CAD using different non-invasive and invasive assessment
methods (other than speckle tracking echocardiography).
The earliest other clinical experiences in the domain of sil-
denaﬁl effect on coronaries were started by Herrmann et al.5
who assessed the systemic, pulmonary, and coronary hemody-
namic effects (using Doppler wire) of oral sildenaﬁl (100 mg) in
14 men with severe stenosis of at least one coronary artery.
They found that there were no signiﬁcant changes in average
peak coronary ﬂow velocity, coronary–artery diameter, or cor-
onary vascular resistance in response to sildenaﬁl. Adelaide et
al.10 conducted a randomized, double-blind, placebo-con-
trolled cross over trial among 105 men with CAD. All subjects
underwent 2 symptom-limited supine bicycle echocardiograms
Figure 3 Echocardiographic illustration showing changes in PSS from baseline (A) to 1 h after sildenaﬁl intake (B).
Table 2 Predictors of changes in PSS.
Odds ratio, 95% CI P value
Sildenaﬁl intake Segmental PSS 3.23 (1.064–9.807) 0.03
Global PSS 0.9 (0.1–4.2) 0.2
Male gender Segmental PSS 1.33 (0.3–5.7) 0.1
Global PSS 1.2 (0.3–5.1) 0.2
Diabetes Segmental PSS 15 (3.9–57.3) 0.001
Global PSS 0.94 (0.3–3.8) 0.2
Hypertension Segmental PSS 1.07 (0.26–4.4) 0.2
Global PSS 1.2 (0.3–4.6) 0.1
Smoking Segmental PSS 0.8 (0.2–3.3) 0.2
Global PSS 1.09 (0.2–4.1) 0.1
Obesity Segmental PSS 1.2 (0.2–7.1) 0.1
Global PSS 0.93 (0.18–4.3) 0.2
Single vessel LAD disease Segmental PSS 0.93 (0.22–3.8) 0.1
Global PSS 1.3 (0.35–5.1) 0.08
Two vessel (LAD+ LCX) disease Segmental PSS 4.9 (0.9–59.8) 0.02
Global PSS 3.1 (0.25–36) 0.03
Two vessel (LAD+RCA) disease Segmental PSS 0.88 (0.13–2.8) 0.2
Global PSS 0.81 (0.15–2.6) 0.3
Three vessel disease Segmental PSS 0.83 (0.24–4.1) 0.1
Global PSS 0.93 (0.21–3.1) 0.08
LVEF <50% Segmental PSS 1.6 (0.4–6.8) 0.04
Global PSS 2.03 (0.5–7.5) 0.03
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dose of sildenaﬁl (50 or 100 mg) or placebo 1 h before each
exercise test. Exercise capacity was similar with sildenaﬁl use
and placebo use. Exercise heart rate and blood pressure incre-
ments were similar in both groups. Dyspnea or angina devel-
oped in 69 patients who took sildenaﬁl and 70 patients who
took placebo. Halcox et al.11 carried out a trial to study the ef-
fect of sildenaﬁl on coronary and peripheral vascular function,
platelet activation, and myocardial ischemia. The effect of oral
sildenaﬁl on resting coronary vascular tone (measured by ace-
tylcholine and cold-pressor testing), endothelium-dependent
and independent function and platelet activation (measured
by platelet ﬂow cytometry) was measured in 24 patients. They
concluded that sildenaﬁl dilates epicardial coronary arteries,improves endothelial dysfunction and inhibits platelet activa-
tion in patients with CAD.
The present study has not used any method to induce
myocardial ischemia; all parameters were measured at rest.
This is in contrast to Herrmann et al.5 (who used intracoro-
nary adenosine for induction of hyperemia) and Adelaide et
al.10 (who used exercise to induce myocardial ischemia). The
present study enrolled 16 female patients among the tested
population, this is in contrast to others5,10 who enrolled only
male patients. The present study interestingly showed the fact
that the worse is the PSS in female subjects at baseline, the
greater is the improvement in its value after sildenaﬁl use. This
may open the way to further investigate such a result, and also
asks a new question beyond the safety proﬁle of the drug in
48 M. Salem et al.men with CAD; could sildenaﬁl, one day, be prescribed as a
therapeutic modality for those patients?
Regarding the non-invasive assessment of acute hemody-
namic responses (i.e. heart rate, systolic and diastolic blood
pressures) to sildenaﬁl at rest, the results of the current study
were concordant with Adelaide et al.10 in the fact that no ma-
jor hemodynamic deterioration occurred at rest in response to
sildenaﬁl. Taking into consideration that sildenaﬁl did not
signiﬁcantly change the average peak coronary ﬂow velocity
(measured by means of Doppler wire) in Herrmann et al.5
one could expect that PSS of the corresponding ischemic
myocardial segments (measured by speckle tracking) would
not deteriorate after sildenaﬁl intake. This was actually the
case in all subgroups in the current study that showed marginal
changes in PSS after sildenaﬁl use. However, the fact that pa-
tients with DM were the only demographic group that showed
marked and statistically signiﬁcant deterioration in segmental
PSS after sildenaﬁl use is worth mentioning. No studies, to
our knowledge, have investigated this issue but it could be ex-
plained presumptively on the basis of ‘coronary steal
phenomenon’ secondary to affection of the development of
coronary collateral vessels by the diabetic syndrome.12
6. Conclusion
Our data suggest that sildenaﬁl could be considered safe for
treatment of erectile dysfunction in men with stable CAD; it
induced improvements in the peak systolic strain of different
myocardial ischemic territories in patients with angiographi-
cally documented disease who have chronic stable angina.
The drug is well tolerated acutely with minimal side effects.
7. Study limitation
(1) Small sample size.
(2) All parameters were measured at rest.
(3) Radial and circumferential strains were not measured.
(4) Regional wall motion abnormalities before and after sil-
denaﬁl were not measured.
(5) The predictive value of the lesion severity on strain was
not measured.Conﬂict of interest
We conﬁrm that authors have no conﬂict of interest.References
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